Monash Antibody Technologies Facility (MATF) is one of the only high-throughput production facilities in the world generating novel custom-made, high-affinity monoclonal antibodies. It has been established to provide a global source of reagents for researchers in academia and industry, and to continuously advance proteomics-level technology developments.
The platform provides for electrophysiological investigation by sharp electrode and patch-clamp recordings. Imaging includes 3 confocal microscopes, laser microdissection, conventional multi-wavelength fluorescence and high resolution white light microscopy.
This shared resource – incorporating the AAHL Biosecurity Microscopy Facility (ABMF) – provides world-class infrastructure and related technology platforms for researchers conducting projects requiring a high biocontainment/biosecure environment.
The Burnet ImmunoMonitoring Facility is accredited in NATA’s R&D Program and offers immunological testing and sample biobanking for vaccine manufacturers, biotechnology and pharmaceutical companies, universities, and research institutes involved in translational research and development of novel therapies.
The HTCS Facility houses a Lead Discovery library currently containing ~200,000 compounds and robotics platforms to screen these small molecule chemical entities against biological targets of interest for drug discovery or for chemical biology outcomes. It has two core automation systems, the Hamilton MicroSTAR and PerkinElmer Minitrak IX systems as [...]
A member of the RNAi Global Initiative, the Functional Genomics Group at the Peter MacCallum Cancer Centre is open to the Australian medical research community for the purpose of providing access to both small interfering (siRNA) and lentiviral-based short hairpin RNAi (shRNAmir) gene knockdown screens for functional genomics studies.
The Molecular Interactions Group (Tachedjian Lab) has developed the capacity and capability to screen compounds for their ability to inhibit human immunodefiency virus (HIV) replication using principals as outlined in the FDA guidelines for Antiviral Product Development. The lab can also screen for inhibitors of herpes simplex virus type I [...]
Baker IDI has considerable research expertise in the areas of proteomics, lipidomics, metabolomics, genomics and epigenomics. The DNA & Blood Profiling Facility (commonly referred to as the “omics”) integrates these research disciplines so health problems can be examined from a multifaceted viewpoint. The central idea behind the new facility is [...]
Development, validation and small- to mid-scale manufacture of ELISA and rapid, point of care diagnostic assays for proteins or antibodies of interest. Documentation and technology transfer to end manufacturers. Access by: Research collaboration. Fee for service.
The facility is equipped for patch-clamp electrophysiology, allowing plasma-membrane ion-channel or transporter activity to be recorded in whole-cell or excised membrane patch configurations. In addition lipid-bilayer recording apparatus allows recording of activity of purified ion-channel or transporter proteins in a minimal system, incorporated in an artificial membrane. Access by: Research [...]